Tumors with mutations in RAS genes can activate the MAPK pathway independently of EGFR. Current NCCN guidelines recommend genotyping of tumor tissue for RAS in all patients with metastatic CRC at diagnosis. DNA sequencing or FISH can be used to detect RAS mutations, but no specific methodology is recommended. Tap the arrow to learn more about specific genetic mutations.